ECO Animal Health Group plc Year End Results

HIGHLIGHTS

• Over 16 per cent increase to £6.4 million (2010: £5.5 million) in profit attributable to shareholders before interest, tax, depreciation, amortisation, share based payments, impairment, foreign exchange and minorities.
• 24.4 per cent advance in turnover on continuing activities to £27.1 million (2010: £21.7 million)
• 30 per cent uplift in dividend to 3.0 pence per share (2010: 2.3 pence)
• £8.5 million of cash generated from operating activities during year (2010: £3.3 million)
• Aivlosin® sales advance over 30 per cent.
• Over 30 per cent total sales growth in key emerging markets – China, India and Latin America
• Aivlosin® manufacturing facility approved by US Federal Drug Administration
• Sales of antiparasitic drugs (Ecomectin®, Ecotraz and others) benefit from increased demand in China, Japan and South Africa and the launch of the Ecomectin® range in Mexico.

Peter Lawrence, Executive Chairman of ECO Animal Health Group plc, commented:
“ECO Animal Health Group has delivered another strong set of results for the year ended 31 March 2011 and the current year has started well. Demand from China, our largest market, is strong and we continue to build our presence there and in our other important territories. We remain optimistic that we shall soon receive FDA clearance to commence sales of Aivlosin® in the US, a step which will have a very significant and exciting impact on the development of the company. Overall, Eco is well positioned with an excellent product range, exciting growth opportunities and potentially very important new products in the development phase. The company is poised to accelerate its growth and continue to deliver value to its shareholders.”